Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. filings document the regulatory record for a Nasdaq-listed diagnostics company focused on cell-free DNA and precision medicine. Recent Form 8-K reports furnish results of operations and financial condition, press releases, investor presentations and exhibit information tied to quarterly and annual reporting.
The company’s proxy materials describe board composition, director elections, committee assignments, executive compensation, equity-award disclosures and stockholder voting matters. Its filings also identify the registered common stock class, Nasdaq Global Select Market listing, governance actions and other material-event disclosures relevant to Natera’s public-company reporting.
Natera, Inc. executive Solomon Moshkevich, President of Clinical Diagnostics, sold a total of 3,405 shares of common stock on May 1, 2026 in multiple open-market transactions, at prices around $200–$207 per share.
According to the disclosures, part of the sale was made to satisfy tax withholding and remittance obligations tied to the vesting of restricted stock units, under written instructions intended to meet Rule 10b5-1(c) conditions. Additional shares were sold under a separate Rule 10b5-1 trading plan adopted on November 26, 2024. After these transactions, he directly holds 142,295 shares of Natera common stock.
Natera, Inc. president and chief business officer John Fesko reported an open-market sale of 291 shares of common stock at $206.16 per share. After the transaction, he directly held 187,220 shares. The footnote states the sale was made to cover tax withholding obligations from RSU vesting under a written instruction intended to satisfy Rule 10b5-1(c) conditions.
Natera, Inc. director and CEO Steven Leonard Chapman reported an open-market sale of 902 shares of Common Stock on May 1, 2026 at $206.16 per share. According to a footnote, the sale was made to satisfy tax withholding and remittance obligations tied to vesting RSUs under a pre-arranged instruction intended to meet Rule 10b5-1(c) conditions. After this transaction, he directly owned 149,867 shares of Natera common stock.
Natera, Inc. disclosed that its Secretary and Chief Legal Officer, Daniel Rabinowitz, executed an open-market sale of 330 shares of common stock on May 1, 2026 at $206.16 per share. After this transaction, he directly held 222,694 shares.
According to the footnote, the sale was made to cover tax withholding and remittance obligations related to the vesting of restricted stock units and was carried out under a written instruction intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Michael Brophy submitted a Form 144 notifying proposed sales of common stock linked to Restricted Stock Units. The filing lists 482 RSUs dated 04/30/2026 and recent 10b5-1 sales on 04/29/2026 (3,070 shares for $594,789.17), 04/27/2026 (1,993 shares for $406,855.83), and 03/10/2026 (785 shares for $160,244.17). The broker listed is Morgan Stanley Smith Barney LLC.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice regarding 3,000 Performance Shares associated with the issuer, dated 01/14/2026. The filing lists multiple recent open-market sales by Solomon Moshkevich in 2026, with individual transactions and proceeds recorded between 02/02/2026 and 04/29/2026.
Natera Inc reports a Schedule 13G showing Vanguard Capital Management beneficially owns 7,205,939 shares of Common Stock, representing 5.08% of the class.
The filing states Vanguard Capital Management has sole dispositive power over 7,205,939 shares and sole voting power for 1,197,443 shares. Ownership is reported on behalf of Vanguard funds and managed accounts.
Natera, Inc.'s Chief Financial Officer, Michael Burkes Brophy, reported selling a total of 5,063 shares of Common Stock in open-market transactions on April 27 and April 29, 2026, at prices around the low-$200 to high-$190 range per share.
According to the footnotes, these sales were carried out to cover tax withholding and remittance obligations tied to the vesting of Restricted Stock Units granted in 2023 and 2024, and were executed under a pre-arranged Rule 10b5-1 trading plan. After the transactions, he directly holds 58,291 shares, indicating he retains a substantial equity stake.
Natera, Inc. CEO and President Steven Leonard Chapman reported selling a total of 5,838 shares of Natera common stock in open-market transactions on April 27, 2026. The footnotes state these sales were made to cover tax withholding and remittance obligations tied to the vesting of Restricted Stock Units and were executed under written instructions intended to satisfy Rule 10b5-1(c) affirmative defense conditions.
Natera, Inc. President and Chief Business Officer John Fesko sold a total of 1,688 shares of common stock on April 27, 2026 in two open-market transactions at prices of about $204 per share. According to the disclosure, these sales were executed to satisfy tax withholding and remittance obligations arising from the vesting of Restricted Stock Units and were carried out under written instructions intended to meet the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.